These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7554777)

  • 1. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects.
    Stevens MJ; Feldman EL; Greene DA
    Diabet Med; 1995 Jul; 12(7):566-79. PubMed ID: 7554777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide as a potential bridge between the metabolic and vascular hypotheses of diabetic neuropathy.
    Stevens MJ
    Diabet Med; 1995 Apr; 12(4):292-5. PubMed ID: 7600740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.
    Cameron NE; Eaton SE; Cotter MA; Tesfaye S
    Diabetologia; 2001 Nov; 44(11):1973-88. PubMed ID: 11719828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy.
    Cameron NE; Cotter MA
    Diabetes; 1997 Sep; 46 Suppl 2():S31-7. PubMed ID: 9285496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications.
    Cameron NE; Cotter MA
    Diabetes Metab Rev; 1994 Oct; 10(3):189-224. PubMed ID: 7835170
    [No Abstract]   [Full Text] [Related]  

  • 6. How does glucose generate oxidative stress in peripheral nerve?
    Obrosova IG
    Int Rev Neurobiol; 2002; 50():3-35. PubMed ID: 12198815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldose reductase in the etiology of diabetic complications. 3. Neuropathy.
    Stribling D; Armstrong FM; Perkins CM; Smith JC
    J Diabet Complications; 1989; 3(3):139-48. PubMed ID: 2528557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications: neuropathy, pathogenetic considerations.
    Greene DA; Sima AA; Stevens MJ; Feldman EL; Lattimer SA
    Diabetes Care; 1992 Dec; 15(12):1902-25. PubMed ID: 1464245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies.
    Cameron NE; Cotter MA
    Diabet Med; 1993; 10(7):593-605. PubMed ID: 8403819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Hara T; Sasaki H; Chaya S; Komori T; Nakashima E; Naruse K; Kato K; Takeuchi N; Kasuya Y; Hotta N
    J Pharmacol Exp Ther; 1998 Dec; 287(3):897-902. PubMed ID: 9864270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
    Cameron NE; Cotter MA; Hohman TC
    Diabetologia; 1996 Feb; 39(2):172-82. PubMed ID: 8635669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular factors in diabetic neuropathy.
    Tesfaye S; Malik R; Ward JD
    Diabetologia; 1994 Sep; 37(9):847-54. PubMed ID: 7806013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and vascular factors in the pathogenesis of diabetic neuropathy.
    Ward JD
    Clin Invest Med; 1995 Aug; 18(4):267-74. PubMed ID: 8549012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of oxidative stress in diabetic vascular and neural disease.
    Yorek MA
    Free Radic Res; 2003 May; 37(5):471-80. PubMed ID: 12797466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.
    Cameron NE; Cotter MA
    Diabetes Res Clin Pract; 1999 Sep; 45(2-3):137-46. PubMed ID: 10588366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.
    Pop-Busui R; Marinescu V; Van Huysen C; Li F; Sullivan K; Greene DA; Larkin D; Stevens MJ
    Diabetes; 2002 Aug; 51(8):2619-28. PubMed ID: 12145179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat.
    Stevens MJ; Dananberg J; Feldman EL; Lattimer SA; Kamijo M; Thomas TP; Shindo H; Sima AA; Greene DA
    J Clin Invest; 1994 Aug; 94(2):853-9. PubMed ID: 8040341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the pathogenesis of diabetic neuropathy.
    Obrosova IG
    Curr Diab Rep; 2003 Dec; 3(6):439-45. PubMed ID: 14611738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrergic neurodegeneration in cerebral arteries of streptozotocin-induced diabetic rats: a new insight into diabetic stroke.
    Cellek S; Anderson PN; Foxwell NA
    Diabetes; 2005 Jan; 54(1):212-9. PubMed ID: 15616031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.